Tobevibart (VIR-3434)
Monoclonal antibody
Also known as BRII-877
Evidence outlook · registrational
Chronic Hepatitis Delta: topline reported 2026-11-08
Its supporting mid-stage studies have completed. The sponsor reported topline results on 2026-11-08 (ECLIPSE 1 Phase 3 meets its primary endpoint). The announcement is listed under Regulatory events.
Latest reported trial: SOLSTICE (NCT05461170) · Phase 2 · met primary endpoint · grade pending
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ECLIPSE 1 NCT06903338 · Chronic Hepatitis Delta Registry: NCT06903338 | 3 | HDV RNA < Lower Limit of Quantification (LLOQ), Target Not Detected (TND) and alanine aminotransferase (ALT) normalization (ALT </= Upper Limit of Normal [ULN]) at Week 48 for Arm 1 vs at Week 12 for Arm 2 (Up to 48 weeks); Incidence of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 12 (Up to 12 weeks) 2026-09-30 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 2 more trials
ECLIPSE 2 NCT07128550 · Chronic Hepatitis Delta Registry: NCT07128550 | 3 | HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24; HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatment. 2026-12 | In progress: results expected 1 Dec 2026 | not yet graded | link ↗ |
SOLSTICE NCT05461170 · Chronic Hepatitis Delta Registry: NCT05461170 | 2 | Proportion of participants with undetectable HDV RNA (< limit of detection [LOD]) or ≥ 2 log10 decrease in HDV RNA from baseline and alanine aminotransferase (ALT) normalization (ALT < upper limit of normal [ULN]) at Week 24 (Up to 24 Weeks); Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Up to 360 Weeks) 2031-11 | Week 24 combined response (HDV RNA undetectable or 2-log decline plus ALT normalization): 70% (23 of 33) with tobevibart and 47% (15 of 32) with tobevibart plus elebsiran (SOLSTICE, NEJM; open-label, no control arm). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
3 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Chronic Hepatitis Delta: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tobevibart (VIR-3434): this drug | Phase 3 | Monoclonal antibody | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| Hepatitis B Immune Globulin (HepaGam B) | Approved(overall) | Protein / enzyme therapeutic | HBsAg | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Hepalatide | Phase 3 | Peptide | NTCP | not yet graded | No reviewed efficacy summary in this indication | |
| Hepatitis B Immune Globulin (I.V.-Hepabig) | Phase 3(overall) | Polyclonal Antibody (human Hepatitis B Immunoglobulin) | HBsAg | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Libevitug (HH-003) | Phase 3 | Monoclonal antibody | HBV/HDV large envelope protein (PreS1 domain) | not yet graded | No reviewed efficacy summary in this indication | |
| ACT201 | Phase 1(overall) | RNA / oligonucleotide | HBsAg | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tobevibart (VIR-3434) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent